Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Thierry Conroy(Inserm), Michel Ducreux(Université Paris-Saclay), Gerald W. Prager(Comprehensive Cancer Center Vienna), Karin Haustermans(Radboud University Nijmegen), Thomas Seufferlein(Universität Ulm), Per Pfeiffer(University of Southern Denmark), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Talia Golan(Sheba Medical Center), Arndt Vogel(Princess Margaret Cancer Centre), Thilo Hackert(Universität Hamburg), Ángela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Valérie Vilgrain(Inserm)
Cited by 502
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k